Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1469 safety and immunogenicity study in African participants
PACTR202609711914086Phase 1Not yet recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of mRNA-1469 in Ebola virus disease (EVD) (4 arms), sponsored by Moderna Inc. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mRNA-1469
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202609711914086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609711914086.